insight, page-8

Rifici,

You do not know what you are talking about with your following misleading statement.

“They are a long way from getting any earnings and this is what the market cares about.”

This is from the recent quarterly which is clearly earnings.

For the December 2012 quarter, sales of $838,000 compared to $341,000 in 2011
and $584,000 in the September 2012 quarter. Sales of Bronchitol for the quarter were
$455,000 compared to $237,000 in the September 2012 quarter, with Germany and
Australia making up approximately 67% and 29% of Bronchitol sales respectively.

http://www.pharmaxis.com.au/assets/pdf/2013/2013_01_23_Pharmaxis_Quarterly_Report_No_37_Dec_2012.pdf